Casirivimab/Imdevimab: Possible Candidate for COVID-19 Treatment in Pets: Traditional Review

The coronavirus disease-2019 (COVID-19), over the last 3 years has globally resulted in catastrophic widespread losses. Prevention and control of this disease become a global priority for researchers medical professionals due to high mortality rates, treatment costs various losses (economic fatalities). In recent times, fact that cats dogs living households which are being affected by caused panic among pet owners animal lovers. Studies have shown cats, especially young group animals most affected. Therefore, COVID-19 is an important topic veterinary medicine. Monoclonal antibodies also been considered possible modality use agents treat lack clear demonstration their efficacy. Casirivimab/imdevimab (CAS/IMD) monoclonal antibody cocktail approved treating COVID-19. There was expectation CAS/IMD combination directly affects angiotensin converting enzyme-2 receptors, plays role pathogenesis virus. Experimental clinical studies positively prognosis patients suffering from COVID-19, speeds up recovery process increases survival. We suggest can be protective positive cats. aim article review related beneficial effects its effectiveness with promote research future studies.